Fig. 4: PTEN status influences the expression of PERK in BRAF V600E-mutated-resistant melanoma.
From: PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
a Western blot showed the indicated protein level in A375sm. C, empty vector; PTEN KO, PTEN knockout by gene editing; PTEN KOR, PTEN knockout A375sm resistance to BRAF inhibition. b Cell viability curves of A375sm with empty vector (A375sm C), A375sm PTEN knockout (A375sm-PTEN KO), and its BRAF inhibitor-resistant counterpart A375sm PTEN KO-R (A375sm-PTEN KOR) cells in response to PLX4032 were determined using CCK8 assay. Error bars denote s.d. for biological three repeats. c Cell viability curves of A375sm with empty vector (A375sm C), A375sm PTEN knockout (A375sm-PTEN KO), and its BRAF inhibitor-resistant counterpart A375sm PTEN KO-R (A375sm-PTEN KOR) cells in response to PERK inhibitor GSK2606414 were determined using CCK8 assay. Error bars denote s.d. for biological three repeats. d Western blot showed the indicated protein level in WLH6215 transfected with empty vector (C) and PTEN. C, empty vector; PTEN OV, PTEN overexpressing; PTEN OVR, PTEN overexpressing WLH6215 resistance to BRAF inhibition. e Cell viability curves of WLH6215 with empty vector (WLH6215 C), WLH6215 PTEN overexpressing (WLH6215 PTEN OV), and its BRAF inhibitor-resistant counterpart WLH6215 PTEN OV-R (WLH6215 PTEN OVR) cells in response to PLX4032 were determined using CCK8 assay. Error bars denote s.d. for biological three repeats. f Cell viability curves of WLH6215 with empty vector (WLH6215 C), WLH6215 PTEN OV (WLH6215 PTEN OV), and its BRAF inhibitor-resistant counterpart WLH6215 PTEN OVR (WLH6215 PTEN OVR) cells in response to PERK inhibitor GSK2606414 were determined using CCK8 assay. Error bars denote s.d. for biological three repeats.
